FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063253996> ?p ?o ?g. }

• W2063253996 endingPage "485" @default.
• W2063253996 startingPage "472" @default.
• W2063253996 abstract "Diabetic MedicineVolume 6, Issue 6 p. 472-485 Regulatory peptides, the hypothalamus and diabetes Dr. G. Williams, Corresponding Author Dr. G. Williams Department of Medicine, The University of Liverpool and Department of Endocrinology, Royal Postgraduate Medical School, London, UKDepartment of Medicine, The University of Liverpool, PO Box 147, Liverpool, L69 3BX, UKSearch for more papers by this authorS.R. Bloom, S.R. Bloom Department of Medicine, The University of Liverpool and Department of Endocrinology, Royal Postgraduate Medical School, London, UKSearch for more papers by this author Dr. G. Williams, Corresponding Author Dr. G. Williams Department of Medicine, The University of Liverpool and Department of Endocrinology, Royal Postgraduate Medical School, London, UKDepartment of Medicine, The University of Liverpool, PO Box 147, Liverpool, L69 3BX, UKSearch for more papers by this authorS.R. Bloom, S.R. Bloom Department of Medicine, The University of Liverpool and Department of Endocrinology, Royal Postgraduate Medical School, London, UKSearch for more papers by this author First published: August 1989 https://doi.org/10.1111/j.1464-5491.1989.tb01213.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Tatemoto K., Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 1980; 285: 417–418. 2 Brown MR, Vale W. Bombesin: putative mammalian neurogastrointestinal peptide. Trends Neurosci 1979; 2: 95–97. 3 SM Wood, JM Polak, SR. Bloom Neuropeptides in the control of the islets of Langerhans. In: AJ Szabo, ed. CNS regulation of carbohydrate metabolism. New York: Academic Press, 1983: 401–420. 4 Ahren B., Taborsky GJ, Pone D. Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. Diabetologia 1986; 29: 827–836. 5 Crowe R., Lincoln J., Blackley PF, Pryor JP, Lumley JSP, Burnstock G. Vasoactive intestinal polypeptide-like immunoreactive nerves in diabetic penis. Diabetes 1983; 32: 1075–1077. 6 Diani AR, Peterson T., Sawada GA, et al. Elevated levels of vasoactive intestinal peptide in the eye and urinary bladder of diabetic and prediabetic Chinese hamsters. Diabetologia 1985; 28: 302–307. 7 Ariznavarretta C., Fernandez-Durango R. Influence of streptozotocin-induced diabetes on the concentration of immunoreactive somatostatin in the retina and peripheral blood of the rat: effect of insulin treatment. J Endocrinol 1987; 114: 363–367. 8 Bauman M., Conlon JM. Changes in the somatostatin, substance P and vasoactive intestinal polypeptide content of the gastrointestinal tract following streptozotocin-induced diabetes in the rat. Diabetologia 1985; 28: 355–358. 9 Belai A., Burnstock G. Selective damage of intrinsic calcitonin gene-related peptide-like immunoreactive enteric nerve fibres in streptozotocin-induced diabetic rats. Gastroenterology 1987; 92: 730–734. 10 Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 1979; 59: 719–809. 11 R. Bleier, W. Byne Septum and hypothalamus. In: G. Paximos, ed. The Rat Nervous System, vol. 1. Sydney, Australia: Academic Press, 1985: 87–118. 12 Frohman LA. CNS peptides and glucoregulation. Ann Rev Physiol 1983; 45: 95–107. 13 Ishikawa K., Taniguchi Y., Kurosumi K., Suzuki M., Shinoda M. Immunohistochemical identification of somatostatin-containing neurons projecting to the median eminence of the rat. Endocrinology 1987; 121: 94–97. 14 Witkin J., Paden CM, Silverman A. The luteinizing hormone-releasing hormone (LHRH) systems in the rat brain. Neuroendocrinology 1982; 35: 429–438. 15 Everitt BJ, Meister B., Hökfelt T., et al. The hypothalamic arcuate nucleus-median eminence complex: immuno-histochemistry of transmitters, peptides and DARPP-32 with special reference to coexistence in dopaminergic neurones. Brain Res Rev 1986; 11: 97–115. 16 Chronwall BM. Anatomy and physiology of the neuroendocrine arcuate nucleus. Peptides 1985; 6 (suppl 2): 1–11. 17 Chronwall BM, di Maggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donoghue TL. The anatomy of neuropeptide Y-containing neurones in rat brain. Neuroscience 1985; 15: 1159–1181. 18 Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev 1987; 8: 256–287. 19 P. Gibbs, GP. Smith The neuroendocrinology of postprandial satiety. In: L. Martini, WF Ganong, eds. Frontiers in Neuroendocrinology, vol 8. New York: Raven Press, 1984: 223–245. 20 Leibowitz SF. Brain monoamines and peptides: role in the control of eating behaviour. Fed Proc 1986; 45: 1396–1403. 21 Maddison S. Intraperitoneal and intracranial cholecystokinin depress operant responding for food. Physiol Behav 1977; 19: 819–826. 22 Posner BI. Insulin interaction with the central nervous system: nature and possible significance. Proc Nutr 1987; 46: 97–105. 23 Smith GP, Jerome C., Custrin BJ, Eterno R., Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in rat. Science 1981; 213: 1036–1037. 24 Tsai SH, Passato E., Lin MT. Cholecystokinin acts through catecholaminergic mechanisms in the hypothalamus to influence ingestive behaviour in the rat. Neuropharmacology 1984; 23: 1351–1356. 25 Morley JE, Levine AS, Yim GKW, Lowy MT. Opioid modulation of appetite. Neurosci Behav Rev 1983; 7: 281–287. 26 Kruth UA, Friesen HG. Changes of beta-endorphin and somatostatin concentrations in different hypothalamic areas of female rats after chronic starvation. Life Sci 1983; 33: 827–830. 27 Kyrkouli S., Stanley BG, Leibowitz SF. Galanin: stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur J Pharmacol 1986; 122: 159–160. 28 Dey PK, Feldberg W. Hyperglycaemia produced by drugs with analgesic properties introduced into the cerebral ventricles of cats. Br J Pharmac 1975; 54: 163–170. 29 Brown M., Taché Y., Fisher D. Central nervous system action of bombesin: Mechanism to induce hyperglycemia. Endocrinology 1979; 105: 660–665. 30 Van Loon GR, Appel NM. β-endorphin-induced hyperglycaemia is mediated by increased central sympathetic outflow to adrenal medulla. Brain Res 1981; 204: 236–241. 31 Brown MR, Rivier J., Vale W. Somatostatin: central nervous system action on glucoregulation. Endocrinology 1979; 104: 1709–1715. 32 Iguchi A., Matsunaga H., Nomura T., Gotoh M., Sakamoto N. Glucoregulatory effects of intrahypothalamic injections of bombesin and other peptides. Endocrinology 1984; 114: 2242–2246. 33 Brown M. Neuropeptides: central nervous system effects on nutrient metabolism. Diabetologia 1981; 20: 299–304. 34 Schneider BS, Monahan JW, Hirsch J. Brain cholecystokinin and nutritional status in rats and mice. J Clin Invest 1979; 64: 1348–1356. 35 Baile DA, Della-Fera MA. Peptidergic control of food intake in food-producing animals. Fed Proc 1984; 43: 2898–2902. 36 Brazeau P., Vale WL, Bürgus R., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive growth hormone. Science 1973; 179: 77–79. 37 Pradayrol L., Jornvall H., Mutt V., Riber A. N-terminally extended somatostatin: the structure of somatostatin-28. FEBS Lett 1980; 109: 55–58. 38 Reichlin S. Somatostatin (parts 1 and 2). New Engl J Med 1983; 309: 1495–1501, 1556–1563. 39 Polak JM, Bloom SR. Somatostatin localisation in tissues. Scand J Gastroenterol 1986; 21 (suppl 119): 11–21. 40 Grube D., Eckedt I., Speck PT, Wagner H-J. Immunohisto-chemistry and microanatomy of the islets of Langerhans. Biomed Res 1983; 4 (suppl): 25–36. 41 Larson L-I. Evidence for anterograde transport of secretory granules in processes of gastric paracrine (somatostatin) cells. Histochemistry 1984; 80: 323–326. 42 Ipp E., Dobbs RE, Arimura A., Vale W., Harris V., Unger RH. Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreo-zymin-cholecystokinin and tolbutamide. J Clin Invest 1977; 60: 760–765. 43 Wasada T., Howard B., McCorkle K., Harris V., Unger RH. High plasma free fatty acid levels contribute to the hypersomatostatinemia of insulin deficiency. Diabetes 1981; 30: 358–361. 44 Alberti KGMM, Christensen NJ, Christensen SE, et al. Inhibition of insulin secretion by somatostatin. Lancet 1973; ii: 1299–1301. 45 Taniguchi H., Utsumi M., Hasegawa M., et al. Physiologic role of somatostatin. Insulin release from rat islets treated by somatostatin antisera. Diabetes 1977; 26: 700–702. 46 Adrian TE, Barnes AJ, Long RG, et al. The effect of somatostatin analogs on secretion of growth, pancreatic and gastrointestinal hormones in man. J Clin Endocrinol Metab 1981; 53: 675–681. 47 Barden N., Lavoie M., DuPont A., Cote J., Cote J-P. Stimulation of glucagon release by addition of anti-somatostatin serum to islets of Langerhans in vitro. Endocrinology 1977; 101: 635–638. 48 Krejs GJ, Brown R., Raskin P. Effect of intravenous somatostatin on jejunal absorption of glucose, amino acids, water and electrolytes. Gastroenterology 1980; 78: 26–31. 49 Bloom SR, Mortimer GH, Thorner MO, et al. Inhibition of gastrin and gastric acid secretion by growth-hormone release inhibiting hormone. Lancet 1974; ii: 1106–1109. 50 Boden G., Sivitz MC, Owen OE, Essa-Konmar N., Landar JH. Somatostatin suppresses secretion and pancreatic exocrine secretion. Science 1975; 190: 163–165. 51 Price BA, Jaffe BM, Zinner MJ. Effect of exogenous somatostatin infusion on gastrointestinal blood flow and hormones in the conscious dog. Gastroenterology 1985; 88: 80–85. 52 Lin MT, Chen JJ, Ho LT. Hypothalamic involvement in the hyperglycemia and satiety actions of somatostatin in rats. Neuroendocrinology 1987; 45: 62–67. 53 Danguir J. Food intake in rats is increased by intracerebro-ventricular infusion of the somatostatin analogue SMS 201–995 and is decreased by somatostatin antiserum. Peptides 1988; 9: 211–213. 54 Makino H., Kanatsuka A., Matsushima Y., Yamamoto M., Kumagai A. Effect of streptozotocin administration on somatostatin content of pancreas and hypothalamus in rats. Endocrinol japan 1977; 24: 295–299. 55 Patel YC, Cameron DP, Bankier A. et al. Changes in somatostatin concentration in pancreas and other tissues of streptozotocin diabetic rats. Endocrinology 1978; 103: 917–923. 56 Patel YC, Weir GC. Increased somatostatin content of islets from streptozotocin diabetic rats. Clin Endocrinol 1976; 5: 191–194. 57 Hellman B., Petersson B. Long-term changes of the A1-and A2-cells in the islets of Langerhans with alloxan-diabetes. Endocrinology 1963; 72: 238–242. 58 Hara M., Patton G., Gerich JE. Increased somatostatin release from pancreas of alloxan diabetic rats perfused in vitro. Life Sci 1979; 24: 625–628. 59 Trimble ER, Gerber PPG, Renold AE. Abnormalities of pancreatic somatostatin secretion corrected by in vivo insulin treatment of steptozocin-diabetic rats. Diabetes 1981; 30: 865–867. 60 Schusdziarra V., Rouiller D., Harris V., Unger RH. Origin of peripheral venous hypersomatostatinemia in alloxan diabetic dogs. Endocrinology 1981; 109: 1107–1110. 61 Ruggere MD, Patel YC. Impaired hepatic metabolism of somatostatin-14 in spontaneously diabetic BB rats. Endocrinology 1984; 115: 144–149. 62 Williams G., Steel JH, Cardoso HM, et al. Increased hypothalamic neuropeptide Y concentrations in diabetic rat. Diabetes 1988; 37: 763–772. 63 Richardson SB, Twente S. Somatostatin release from dispersed hypothalamic cells: effects of diabetes. Diabetologia 1987; 30: 893–898. 64 Ipp E., Rivier J., Dobbs RE, Brown M., Vale W., Unger RH. Somatostatin analogs inhibit somatostatin release. Endocrinology 1979; 104: 1270–1273. 65 Tannenbaum GS. Growth hormone secretory dynamics in streptozotocin diabetes: evidence of a role for endogenous circulating somatostatin. Endocrinology 1981; 108: 76–82. 66 Hermansen K. Secretion of somatostatin from the normal and diabetic pancreas. Diabetologia 1980; 19: 492–504. 67 Chiba T., Taminato T., Kadowaki S., et al. Reversal of increased gastric somatostatin in streptozotocin-diabetic rats by whole pancreas transplantation. Diabetes 1981; 30: 724–727. 68 Dolais-Kitabgi J., Le Marchand-Brustel Y., Freychet P. Somatostatin in the pancreas and hypothalamus of obese mice. Diabetologia 1979; 17: 257–261. 69 Makino H., Matsushima Y., Kanatsuka A., Yamamoto M., Kumagai A., Nishimura M. Changes in pancreatic somatostatin content in spontaneously diabetic mice, as determined by radioimmunoassay and immunohisto-chemical methods. Endocrinology 1979; 104: 243–247. 70 Patel YC, Orci L., Bankier A., Cameron DP. Decreased pancreatic somatostatin (SRIF) concentration in spontaneously-diabetic mice. Endocrinology 1976; 99: 1415–1418. 71 Patel YC, Cameron DP, Stefan Y., Malaisse-Lagae F., Orci L. Somatostatin: widespread abnormality in tissues of spontaneously diabetic mice. Science 1977; 198: 930–931. 72 Berelowitz M., Coleman DL, Frohman LA. Temporal relationship of tissue somatostatin-like immunoreactivity to metabolic changes in genetically obese and diabetic mice. Diabetes 1980 29: 717–723. 73 Basabe JC, Karabatas LM, Arata M., Pivetta OH, Cresto JC. Secretion and effect of somatostatin in early stages of the diabetic syndrome in C57BL/KsJ-mdb mice. Diabetologia 1986; 29: 485–488. 74 Herberg L.; Coleman DL. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 1977; 26: 59–99. 75 Petersson B., Eide R., Efendic S., et al. Somatostatin in the pancreas, stomach and hypothalamus of the diabetic Chinese hamster. Diabetologia 1977; 13: 463–466. 76 Williams G., Ghatei MA, Diani AR, Gerritsen GC, Bloom SR. Reduced hypothalamic somatostatin and neuropeptide Y concentrations in the spontaneously diabetic Chinese hamster. Horm Metab Res 1988; 20: 668–670. 77 Gerritsen GC, Blanks MC, Miller RL, Dulin WE. Effect of diet limitation on the development of diabetes in prediabetic Chinese hamsters. Diabetologia 1974; 10: 559–565. 78 Orci L., Baetens D., Rufener C., et al. Hypertrophy and hyperplasia of somatostatin containing D-cells in diabetes. Proc Natl Acad Sei USA 1976; 73: 1338–1342. 79 Stefan Y., Orci L., Malaisse-Lagae F., Perrelet A., Patel Y., Unger RH. Quantitation of endocrine cell content in the pancreas of non-diabetic and diabetic humans. Diabetes 1982; 31: 694–700. 80 Rahier J., Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24: 366–371. 81 Foulis AK, Stewart JA. The pancreas in recent-onset Type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 1984; 26: 456–461. 82 Skare S., Dahl-Jorgensen K., Hanssen KF, Norman N. Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin-dependent diabetes mellitus without residual B-cell function. Acta Endocrinol 1985; 109: 517–521. 83 Binimelis J., Webb SM, Serrano J., et al. Plasma immuno-reactive somatostatin is elevated in diabetic ketoacidosis and correlates with plasma non-esterified fatty acid concentration. Diabetic Med 1987; 4: 221–224. 84 Grill V., Gutniak M., Roovete A., Efendic S. A stimulating effect of glucose on somatostatin release is impaired in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1984; 59: 293–305. 85 Gutniak M., Grill V., Efendic S. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in non-insulin-dependent diabetes mellitus: evidence for more than one mechanism of action. J Clin Endocrinol Metab 1986; 62: 77–83. 86 Miyazaki K., Funakoshi A., Ibayashi H. Plasma somatostatin-like immunoreactivity responses to a mixed meal and the heterogeneity in healthy subjects and non-insulin-dependent (NIDDM) diabetics. Endocrinol japan 1986; 33: 519–559. 87 Itoh M., Hirooka Y., Nihei N. Response of plasma somatostatin-like immunoreactivity (SLI) to a 75g oral glucose tolerance test in normal subjects and patients with impaired glucose tolerance. Acta Endocrinol 1983; 104: 468–474. 88 Vinik Al, Lewitt NS, Pimstone BL, Wagner L. Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycaemia and a mixed meal in healthy subjects and in non-insulin dependent maturity onset diabetes. J Clin Endocrinol Metab 1981; 52: 330–337. 89 Raskin P., Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. New Engl J Med 1978; 299: 433–436. 90 Reaven GM, Chen Y-DI, Golay A., Swislocki ALM, Jaspan JB. Documentationof hyperglucagonemia throughout the day in non-obese and obese patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106–110. 91 Hansen AP. Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 1980; 49: 1467–1478. 92 Hayford JT, Danney MM, Hendrix JA, Thompson RG. Integrated concentrations of growth hormone in juvenile-onset diabetics. Diabetes 1980; 29: 391–398. 93 Press M., Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. New Engl J Med 1984; 310: 810–815. 94 Gerich JE. Role of growth hormone in diabetes mellitus. New Engl J Med 1984; 310: 848–850. 95 Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. New Engl J Med 1985; 312: 1473–1479. 96 Kollind M., Adamson U., Lins PE. Insulin resistance following nocturnal hypoglycaemia in insulin-dependent diabetes mellitus. Acta Endocrinol 1987; 116: 314–320. 97 Grant M., Russell B., Fitzgerald C., Merimee TJ. Insulinlike growth factors in vitreous. Studies in control and diabetic subjects with neovascularisation. Diabetes 1986; 35: 416–420. 98 Gerich JE, Lorenzi M., Schneider V., Karam JH, Rivier J., Guillemin R., Forsham PH. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. New Engl J Med 1974; 291: 544–547. 99 del Guercio MJ, di Natale B., Gargantini L., Garlaschi C., Chiumello G. Effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels in diabetic children. Diabetes 1976; 25: 550–553. 100 Gerich JE, Schultz TA, Lewis SB, Karam JA. Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. Diabetologia 1977; 13: 537–544. 101 Christensen S., Hansen A., Weeke J., Lundbaek K. 24-hour studies of the effect of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics. Diabetes 1978; 27: 300–307. 102 Dimitriadis G., Tessari P., Gerich J. Effects of a long-acting somatostatin analogue on postprandial hyperglycemia in insulin-dependent diabetes mellitus. Metabolism 1983; 32: 987–992. 103 Dimitriadis G., Gerich J. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profile in patients with insulin-dependent diabetes. Horm Metab Res 1985; 17: 510–511. 104 Spinas GA, Bock A., Keller U. Reduced post-prandial hyperglycemia after subcutaneous injection of a somatostatin analog (SMS 201-995) in insulin-dependent diabetes mellitus. Diabetes Care 1985; 8: 429–435. 105 Serrano-Rios M., Navascues I., Saban J., Ordonez A., Sevilla F., del Pozo E. Somatostatin analog SMS 201–995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab 1986; 63: 1071–1074. 106 Plewe G., Nolken G., Krause U., del Pozo E., Beyer J. Somatostatin analogue SMS 201–995 in type 1 diabetes mellitus. Initial experience after repeated administration. Scand J Gastroenterol 1986; 21 (suppl 119): 166–169. 107 Wahren J., Felig P. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet 1976; ii: 1213–1216. 108 J. Gerich, I. Gottesman, G. Bolli, P. Campbell, F. Kennedy Treatment of diabetes with L363, 586. In: S. Reichlin, ed. Somatostatin. Basic and Clinical Status. New York: Plenum Press, 1987: 303–312. 109 Scheen AJ, Krzentowski G., Castillo M., Lefebvre PJ, Luykcx AS. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia 1983; 24: 319–325. 110 Stout RW. Overview of the association between insulin and atherosclerosis. Metabolism 1985; 34: 7–12. 111 Chiodini PG, Cozzi R., Dallabonza D., et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 1987; 64: 447–453. 112 Kvols LK, Moertel CG, O'Connell MJ, Schult AJ, Rubin J., Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. New Engl J Med 1986; 315: 663–666. 113 Christensen S., Hansen A., Lundbaek K. Somatostatin in maturity-onset diabetes. Diabetes 1978; 27: 1013–1016. 114 Tamborlane WJ, Sherwin RS, Hendler M., Felig P. Metabolic effects of somatostatin in maturity-onset diabetes. New Engl J Med 1977; 297: 181–185. 115 Bauer W., Briner U., Doepfner W. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sei 1982; 31: 1133–1140. 116 Davies RR, Miller M., Turner SJ, et al. Effects of somatostatin analogue SMS 201–995 in non-insulin-dependent diabetes. Clin Endocrinol 1986; 25: 739–747. 117 Williams G., Füessl H., Kraenzlin M., Bloom SR. Postprandial effects of SMS 201–995 on gut hormones and glucose tolerance. Scand J Gastroenterol 1986; 21 (suppl 119): 73–83. 118 Williams G., Füessl HS, Burrin JM, Chilvers E., Bloom SR. Postprandial glycaemic effects of a long-acting somatostatin analogue (SMS 201-995) in non-insulin dependent diabetes mellitus. Horm Metab Res 1988; 2: 168–170. 119 Williams G., Ball JA, Burrin JM, Joplin GF, Bloom SR. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201–995. Lancet 1986; ii: 774–778. 120 Tatemoto K., Neuropeptide Y.: Complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA 1982; 79: 5485–5489. 121 Allen YS, Adrian TE, Allen JM, et al. Neuropeptide Y distribution in the rat brain. Science 1982; 221: 877–879. 122 de Quidt M., Emson PC. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system. II Immunochemical analysis. Neuroscience 1986; 18: 545–618. 123 Everitt BJ, Hökfelt T., Terenimo L., Tatemoto K., Mutt V., Goldstein M. Differential co-existence of neuropeptide Y (NPY)-like immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscience 1984; 11: 443–453. 124 Pelletier G., Guy J., Allen YS, Polak JM. Electron microscopic immunocytochemical localization of neuropeptide Y (NPY) in the rat brain. Neuropeptides 1984; 4: 319–324. 125 Kerkérian L., Pelletier G. Effects of monosodium-L-glutamate administration on neuropeptide Y-containing neurones in the rat hypothalamus. Brain Res 1986; 364: 388–390. 126 Furness JB, Costa M., Emson PC, et al. Distribution, pathways and reactions to drug treatment of nerves with neuropeptide Y- and pancreatic polypeptide-like immunoreactivity in the guinea-pig digestive tract. Cell Tiss Res 1983; 234: 71–92. 127 Guy, J., Polak JM, Allen JM, et al. High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart. J Histochem Cytochem 1984; 32: 467–477. 128 Ekblad E., Wahlestedt C., Edelund M., Hakanson R., Sundler F. Neuropeptide Y in the gut and pancreas: distribution and possible vasomotor function. Front Horm Res 1984; 12: 85–90. 129 Pernow J., Lundberg JM, Kaijser L. Phentolamine- and clonidine-induced changes in plasma neuropeptide Y-like immunoreactivity during sympathetic activation in man. Clin Physiol 1987; 7: 431–434. 130 Clark JJ, Kalra PS, Crowley WR, Kalra SP. Neuropeptide Y and human pancreatic polypeptide stimulate feeding behaviour in rats. Endocrinology 1984; 115: 427–431. 131 Stanley BG, Daniel DR, Chin AS, Leibowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 1985; 6: 1205–1221. 132 Stanley BG, Kyrkouli SE, Lampert S., Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189–1192. 133 Morley JE, Levine AS, Gosnell BA, Kneip J., Grace M. Effect of neuropeptide Y on ingestive behaviours in the rat. Am J Physiol 1987; 252: R599–609. 134 Steinman JL, Gunion MW, Morley JE. Third and fourth ventricle neuropeptide Y (NPY) stimulates feeding and drinking in rats. Fed Proc 1987; 46: 1125–1129. 135 Sahu A., Kalra PS, Kalra SP. Food deprivation and ingestion induce reciprocal changes in neuropeptide Y concentrations in the paraventricular nucleus. Peptides 1988; 9: 83–86. 136 Williams G., Lee YC, Ball JA, et al. Hypothalamic regulatory peptides in obese Zucker rats: effects of food restriction (Abstract). Clin Sci 1987; suppl 18: 43P. 137 Willoughby JO, Blessing WW. Neuropeptide Y injected into the supraoptic nucleus causes secretion of vasopressin in the unanaesthetised rat. Neurosci Lett 1987; 75: 17–22. 138 Moltz JH, McDonald JK. Neuropeptide Y: direct and indirect action on insulin secretion in the rat. Peptides 1985; 6: 1155–1159. 139 McDonald JK, Lumpkin MD, Samson WK, McCann SM. Neuropeptide Y affects secretion of luteinizing hormone and growth hormone in ovariectomised rats. Proc Natl Acad Sci USA 1985; 82: 561–564. 140 Harfstrand A., Eneroth P., Agnati L., Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul Peptides 1987; 17: 167–179. 141 Harfstrand A., Fuxe K., Agnati LF, et al. Studies on neuropeptide Y-catecholamine interactions in the hypothalamus and in theforebrain of the male rat. Relationship to neuroendocrine function. Neurochem Int 1986; 8: 355–376. 142 Kalra PS, Kalra SP. Steroidal modulation of the regulatory neuropeptides: luteinizing hormone releasing hormone neuropeptide Y and endogenous opioid peptides. J Steroid Biochem 1986; 25: 733–740. 143 Kerkérian L., Guy J., Lefévre G., Pelletier G. Effects of neuropeptide Y (NPY) on the release of anterior pituitary hormones in the rat. Peptides 1985; 6: 1201–1207. 144 Allen LG, Kalra PS, Crowley WR, Kalra SP. Comparison of the effect of neuropeptide Y and adrenergic transmitters on LH release and food intake in male rats. Life Sci 1985; 37: 617–622. 145 Williams G., Cardoso HM, Lee YC, et al. Increased hypothalamic neuropeptide Y (NPY) concentrations in the diabetic BB/E rat (Abstract). Diabetic Med 1988; 5 (suppl 1): 5. 146 Pierson AM, Williams G., Jones PM, et al. Hypothalamic neuropeptide Y mRNA is increased in streptozotocin-diabetic rats (Abstract). Diabetic Med 1988; 5 (suppl 1): 19. 147 Williams G., Gill JS, Lee YC, Cardoso HM, Okpere BE, Bloom SR. Increased neuropeptide Y in specific hypothalamic nuclei of the streptozotocin-diabetic rat. Diabetes 1989; 38: 321–327. 148 Koopmans HS, Pi-Sunyer FX. Large changes in food intake in diabetic rats fed high-fat and low-fat diets. Brain Res Bull 1986; 17: 861–871. 149 Bluet-Pajot MT, Durand D., Kordon C. Influence of streptozotocin-induced diabetes on growth hormone secretion in the rat. Neuroendocrinology 1983; 36: 306–309. 150 Katayama S., Brownscheidle CM, Wooten V., Lee JB, Shimoaka K. Absent or delayed preovulatory luteinizing hormone surge in experimental diabetes mellitus. Diabetes 1984; 33: 324–327. 151 Gonzalez C., Montoya E., Jolin T. Effect of streptozotoc in diabetes on the hypothalamo-pituitary and thyroid axis in the rat. Endocrinology 1980; 107: 2099–2103. 152 Kampa IS, Rosenberg JM, Sideman M., Kampa LL. Prolactin levels in streptozocin-induced diabetic rats. Horm Metab Res 1986; 18: 419–420. 153 Woods SC, Porte D., Bobbioni E., Lonescu E., Sauter J., Rohner-Jeanrenaud F. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. Am J Clin Nutr 1985; 42: 1063–1067. 154 Williams G., Lee YC, Ghatei MA, Flatt PR, Bailey CJ, Bloom SR. Reduced hypothalamic neurotensin concentrations in the ob/ob mouse: evidence for a hypothalamic cause of hyperphagia? (Abstract). Diabetic Med 1988; 5 (suppl 2): 1. 155 Akema T., Praputpittaya C., Kimura F. Effects of preoptic microinjection of neurotensin on luteinizing hormone secretion in unanesthetized ovariectomized rats with or without estrogen priming. Neuroendocrinology 1987; 46: 345–349. 156 W. Vale, J. Rivier, M. Brown Physiology and pharmacology of hypothalamic regulatory peptides. In: PJ Morgane, J. Panksepp, eds. Handbook of the Hypothalamus, vol. 2. New York: Dekker, 1980: 165–252. 157 Vijayan E., McCann SM. In vivo and in vitro effects of substance P and neurotensin on gonadotrophin and prolactin release. Endocrinology 1979; 105: 64–68. 158 Adams E., Venetikou MS, Woods CA, Lacoumenta S., Burrin JM. Neuropeptide Y directly inhibits growth hormone secretion by human pituitary somatotrophic tumours. Acta Endocrinol 1987; 115: 149–154. 159 Harfstrand A. Intraventricular administration of neuropeptide Y (NPY) induces hypotension, bradycardia and bradypnoea in the awake unrestrained male rat. Counteraction by NPY-induced feeding behaviour. Acta Physiol Scand 1986; 128: 121–123. 160 Zini P., Pich LM, Fuxe K., et al. Actions of centrally-administered neuropeptide Y on EEG activity in different rat strains and different phases of their circadian cycle. Acta Physiol Scand 198; 122: 71–77. 161 Albers HE, Ferris CF. Neuropeptide Y: role in light:dark cycle entrainment of hamster circadian rhythms. Neurosci Lett 1984; 50: 163–168. 162 Lundberg JM, Saria A., Anggard A., Hökfelt T., Terenius L. Neuropeptide Y and noradrenaline interaction in peripheral cardiovascular control. Clin Exp Hypertens 1984; 6: 1961–1972. Citing Literature Volume6, Issue6August 1989Pages 472-485 ReferencesRelatedInformation" @default.
• W2063253996 created "2016-06-24" @default.
• W2063253996 creator A5004786685 @default.
• W2063253996 creator A5011196462 @default.
• W2063253996 date "1989-08-01" @default.
• W2063253996 modified "2023-10-14" @default.
• W2063253996 title "Regulatory peptides, the hypothalamus and diabetes" @default.
• W2063253996 cites W1585598978 @default.
• W2063253996 cites W1668646584 @default.
• W2063253996 cites W1902836344 @default.
• W2063253996 cites W1961916454 @default.
• W2063253996 cites W1963581374 @default.
• W2063253996 cites W1964740421 @default.
• W2063253996 cites W1965196193 @default.
• W2063253996 cites W1967950068 @default.
• W2063253996 cites W1974299358 @default.
• W2063253996 cites W1975096719 @default.
• W2063253996 cites W1975799894 @default.
• W2063253996 cites W1976487561 @default.
• W2063253996 cites W1976851510 @default.
• W2063253996 cites W1977714703 @default.
• W2063253996 cites W1978490884 @default.
• W2063253996 cites W1979336017 @default.
• W2063253996 cites W1981609810 @default.
• W2063253996 cites W1981866891 @default.
• W2063253996 cites W1981909794 @default.
• W2063253996 cites W1983010315 @default.
• W2063253996 cites W1983561737 @default.
• W2063253996 cites W1985775724 @default.
• W2063253996 cites W1985939147 @default.
• W2063253996 cites W1988170773 @default.
• W2063253996 cites W1989719288 @default.
• W2063253996 cites W1991620392 @default.
• W2063253996 cites W1995071802 @default.
• W2063253996 cites W1995203483 @default.
• W2063253996 cites W1995956817 @default.
• W2063253996 cites W1996471337 @default.
• W2063253996 cites W1997283204 @default.
• W2063253996 cites W2004068581 @default.
• W2063253996 cites W2005190183 @default.
• W2063253996 cites W2006611896 @default.
• W2063253996 cites W2007176653 @default.
• W2063253996 cites W2007611342 @default.
• W2063253996 cites W2008919826 @default.
• W2063253996 cites W2011274949 @default.
• W2063253996 cites W2014008350 @default.
• W2063253996 cites W2014400191 @default.
• W2063253996 cites W2016572776 @default.
• W2063253996 cites W2016647549 @default.
• W2063253996 cites W2017743951 @default.
• W2063253996 cites W2017797235 @default.
• W2063253996 cites W2017975839 @default.
• W2063253996 cites W2019261163 @default.
• W2063253996 cites W2019605333 @default.
• W2063253996 cites W2020268585 @default.
• W2063253996 cites W2020284995 @default.
• W2063253996 cites W2021667477 @default.
• W2063253996 cites W2022980964 @default.
• W2063253996 cites W2023224640 @default.
• W2063253996 cites W2024483197 @default.
• W2063253996 cites W2029093815 @default.
• W2063253996 cites W2031299737 @default.
• W2063253996 cites W2032458635 @default.
• W2063253996 cites W2033305745 @default.
• W2063253996 cites W2034136869 @default.
• W2063253996 cites W2034194967 @default.
• W2063253996 cites W2034275159 @default.
• W2063253996 cites W2038137092 @default.
• W2063253996 cites W2038393024 @default.
• W2063253996 cites W2039017859 @default.
• W2063253996 cites W2039167652 @default.
• W2063253996 cites W2039214641 @default.
• W2063253996 cites W2039931592 @default.
• W2063253996 cites W2040236029 @default.
• W2063253996 cites W2044251662 @default.
• W2063253996 cites W2044431563 @default.
• W2063253996 cites W2045854722 @default.
• W2063253996 cites W2046628195 @default.
• W2063253996 cites W2046917110 @default.
• W2063253996 cites W2050629955 @default.
• W2063253996 cites W2052519819 @default.
• W2063253996 cites W2057184964 @default.
• W2063253996 cites W2057847950 @default.
• W2063253996 cites W2058306762 @default.
• W2063253996 cites W2059719062 @default.
• W2063253996 cites W2062636887 @default.
• W2063253996 cites W2062728629 @default.
• W2063253996 cites W2064110992 @default.
• W2063253996 cites W2066424490 @default.
• W2063253996 cites W2067421416 @default.
• W2063253996 cites W2067710866 @default.
• W2063253996 cites W2068204752 @default.
• W2063253996 cites W2068535396 @default.
• W2063253996 cites W2068998457 @default.
• W2063253996 cites W2070316919 @default.
• W2063253996 cites W2071310612 @default.
• W2063253996 cites W2075390326 @default.
• W2063253996 cites W2076685145 @default.

• next